Genflow Biosciences CEO discusses key updates and future plans

############################# Video Source: www.youtube.com/watch?v=u_NG-pFt4ZY

Genflow Biosciences PLC CEO Dr Eric Leire takes Proactive's Stephen Gunnion through the leader in longevity research's recent progress and plans. • Leire highlighted three main events. Firstly, the successful securing of funding has enabled the company to advance its programs without delays. Specifically, the focus on lead candidate, GF-1002, has seen significant progress thanks to the guidance from the FDA and the European Agency. • Leire emphasised the importance of maintaining a global reach, aligning efforts in both Europe and the US to maximize market potential. • Leire shared insights on Genflow's innovative approach to delivering sirtuin 6 (SIRT6) variants, particularly in veterinary applications, which has led to promising developments in clinical trials for dogs. This research not only aims to combat age-related diseases in animals but also provides crucial data that could expedite human trials. • Moreover, Genflow's collaboration with Exothera S.A. on a feasibility study for large-scale production of sirtuin 6 variants is a key step towards cost-effective therapies. • As Genflow moves into the second half of 2024, the primary focus will be on preparing for clinical trials on MASH (metabolic-associated steatohepatitis). and advancing the dog study, which could lead to rapid proof of concept and potential collaborations with major veterinary pharmaceutical companies. • Our commitment to advancing these programs while ensuring cost-effectiveness and broad market reach is unwavering, said Dr Leire. • Visit Proactive's YouTube channel for more videos, and don't forget to give this video a like, subscribe to the channel, and enable notifications for future content. • #GenflowBiosciences #DrEricLeire #AgeRelatedDiseases #Sirtuin6 #FDAUpdate #NASHResearch #Biotech #VeterinaryScience #ClinicalTrials #ProactiveInvestors #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

#############################

New on site